Uno degli obiettivi principali di Life4me+ è quello di prevenire nuovi casi di HIV e altre infezioni sessualmente trasmissibili, epatite C e tubercolosi.

L'app aiuta a stabilire una comunicazione anonima tra i medici e le persone sieropositive. Ti consente di organizzare comodamente l'orario di assunzione dei farmaci e di impostare promemoria nascosti e personalizzati.

Indietro
13 agosto 2018, 12:00
847

In the United States approved a new type of female contraceptive

In the United States approved a new type of female contraceptive - immagine 1

The US Food and Drug Administration (FDA) last Friday, August 10, approved the use of the innovative female contraceptive Annovera (a combination of estrogen and segesterone acetate). The contraceptive is an intravaginal ring that can be used by women throughout the year. The possible appearance of the product in the US market is expected in 2020.

As specified in the press-service of the regulator, the contraceptive is interesting because a woman can insert and remove it several times. Annovera works for 3 weeks, after which it is taken out for the period of menstruation (1 week). The ring is designed for 13 cycles of 28 days.

Previously, indicate the developers, the vaginal contraceptive had to be changed monthly. Annovera - the first such contraceptive means of reusable use.

An international non-profit organization, the Population Council, was responsible for creating an innovative tool for women. According to Buzzfeed, the organization has already signed an agreement on the sale of Annovera to TherapeuticsMD.

As noted in the FDA, the new ring is not able to prevent the transmission of HIV and other sexually transmitted infections. In addition, it is contraindicated to women smokers from 35 years, because it can increase the risk of developing cardiovascular diseases, as well as those who have a history of removal of tumors in the breast and undergoing treatment for hepatitis C with certain drugs.

We add that, according to the results of CI, the risk of pregnancy with the use of Annovera was 2-4% while when using classical contraceptives it was equal to 18%.

Autore: Lilia Ten

Condividi sui social media